Table 2. Presenting clinical features and outcomes in Prospective studies of DILI.

Feature	DILIN US N=300 (ref 32)	Spain N=446 (ref 23)	Japan N=1676 (ref 26)	Iceland N=96 (ref 24)	France N=34 (ref 33)
Study Design	Multicenter (8 sites) ‘04 to ‘08	Multicenter (32 sites) ’94-‘05	Multicenter ’97-‘06	Population based ’10-‘12	Population based ’97-‘01
Causality method	Expert opinion	RUCAM	RUCAM	RUCAM	CIOMS
F/U duration (mon)	6 to 24	3	NA	3	3
Mean age (yrs)	48	53	55	55	55
% Female	60%	49%	57%	56%	65%
Race
% Caucasian	79%	100%	0%	100%	100%
% African Amer	11%		0%
% Asian	4%		100%
% Other	6%		0%
Liver injury type
% Hepatocellular	57%	58%	59%	42%	53%
% Mixed/Cholestatic	20%/23%	22%/20%	20%/21%	26%/32%	26%/21%
% Jaundice	69%	71%	NA	27%	29%
% Liver biopsy	50%	25%	NA	11%	NA
% Hospitalized	60%	53%	NA	23%	12%
% Died or transplanted	10%	7%	3.7%	11%	6%
% Chronic	14%	10%	8.4%	7%	NA
Suspect drugs
% Antibiotics	45%	32%	14%	37%	25%
% Psychotropic	15%	17%	10%	7%	22%
% HDS products	9%	0%	17.1%	16%	0%
% Hypolipidemic	3%	3%	0%	3%	13%

NA= Not available